Painful lack of unity highlighted on opioid use guidelines

29 August 2024

A workshop held at the International Association for the Study of Pain (IASP) World Congress has revealed significant discrepancies in clinical practice guidelines (CPGs) across countries for opioid use in chronic pain management. 

These inconsistencies raise concerns about the role of CPGs in the overprescription of opioids, potentially exacerbating the risk of opioid use disorder (OUD) among chronic pain patients, according to GlobalData.

The findings presented at IASP World Congress indicate a perceived need for updated and more stringent CPGs for prescribing opioids in the management of chronic pain.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical